Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX

Rice Hall James & Associates LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 93,396 shares of the company’s stock, valued at approximately $2,369,000. Rice Hall James & Associates LLC owned about 0.23% of Pacira BioSciences at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in shares of Pacira BioSciences by 0.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock valued at $55,751,000 after acquiring an additional 11,831 shares during the last quarter. Balyasny Asset Management L.P. increased its position in Pacira BioSciences by 36.1% in the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after purchasing an additional 565,288 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Impax Asset Management Group plc raised its stake in Pacira BioSciences by 25.0% during the fourth quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock valued at $19,411,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Pacira BioSciences by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock valued at $17,504,000 after purchasing an additional 49,079 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the transaction, the insider owned 216,384 shares in the company, valued at $5,026,600.32. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the transaction, the senior vice president owned 62,284 shares of the company’s stock, valued at $1,463,674. This trade represents a 8.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Trading Up 3.3%

PCRX stock opened at $24.00 on Wednesday. The company has a quick ratio of 3.94, a current ratio of 5.04 and a debt-to-equity ratio of 0.54. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.66. The stock has a market capitalization of $956.64 million, a price-to-earnings ratio of 68.57 and a beta of 0.27. The firm’s fifty day simple moving average is $24.82 and its two-hundred day simple moving average is $23.60.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $192.40 million for the quarter, compared to the consensus estimate of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.74 earnings per share. As a group, analysts anticipate that Pacira BioSciences, Inc. will post 1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PCRX has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Wednesday, July 1st. Truist Financial initiated coverage on shares of Pacira BioSciences in a report on Monday. They issued a “buy” rating and a $30.00 price target for the company. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Needham & Company LLC boosted their price objective on Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $30.20.

Pacira BioSciences Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.